Skip to content

Long term efficacy of oblique anterior lumbar interbody fusion (OLIF) for lumbar degenerative disease

Long term efficacy of oblique anterior lumbar interbody fusion (OLIF) for lumbar degenerative disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018960
Enrollment
Unknown
Registered
2018-10-19
Start date
2017-02-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar degenerative disease

Interventions

OLIF combined fixation:OLIF combined fixation
OLIF alone:OLIF alone
MIS-TLIF:MIS-TLIF

Sponsors

Beijing Jishuitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. the symptoms of lumbago accompanied by pain and numbness of the lower limbs lasted for more than 3 months; 2. Conservative treatment is invalid; 3. imaging data and clinical manifestations are consistent; 4. Patients signed informed consent before surgery; 5. Patients have the ability to act autonomously.

Exclusion criteria

Exclusion criteria: (1) Severe heart disease, arrhythmia and hypertension patients, old and weak, poor general condition, or serious medical diseases such as heart, lung, liver, kidney and other important organ dysfunction and tumor; (2) Patients with coagulation dysfunction and thrombosis; (3) patients taking immunosuppressive drugs; (4) mentally handicapped persons and incompatible authors.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;Oswestry Disability Index;anterior/posterior disc heights;foraminal height;foraminal width;cage subsidence;cage retropulsion;fusion rate;muscle atrophy;

Secondary

MeasureTime frame
disc lordotic angle;lumbar lordotic angle;

Countries

China

Contacts

Public ContactHe Da

Beijing Jishuitan Hospital

2602248877@qq.com+86 13801086756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026